| 刘向东,罗 波.靶向乳腺癌干细胞免疫治疗的研究进展[J].中国肿瘤,2023,32(7):550-556. |
| 靶向乳腺癌干细胞免疫治疗的研究进展 |
| Research Progress in Immunotherapy Targeting Breast Cancer Stem Cells |
| 投稿时间：2023-02-19 |
| DOI：10.11735/j.issn.1004-0242.2023.07.A010 |
|
 |
| 中文关键词: 乳腺癌 肿瘤干细胞 免疫治疗 靶向治疗 |
| 英文关键词:breast cancer cancer stem cell immunotherapy targeted therapy |
| 基金项目:国家自然科学基金（81772499）；湖北省卫健委重点支撑项目（WJ2021Z001）；湖北省肿瘤医院生物医学中心专项科研基金（2022SWZX18） |
|
| 摘要点击次数: 460 |
| 全文下载次数: 96 |
| 中文摘要: |
| 摘 要：乳腺癌是一种高侵袭性的恶性肿瘤。近年来，我国乳腺癌的发病人数逐年增加，其高复发率给乳腺癌患者的生存带来了严重威胁。肿瘤干细胞在乳腺癌的发生及进展中扮演了重要角色，是乳腺癌治疗的关键靶点。因此，开发新的靶向乳腺癌干细胞（breast cancer stem cell，BCSC）的方法对于乳腺癌的治疗至关重要。肿瘤干细胞具有独特的免疫学特性，靶向BCSC的免疫治疗具有巨大的前景。目前已开发的靶向BCSC的免疫疗法包括DC疫苗、CAR-T细胞、免疫检查点抑制剂、溶瘤病毒和单克隆抗体等，为乳腺肿瘤的根除带来了希望。然而，由于缺乏BCSC的特异性标志物，设计有效的BCSC靶向疗法面临着巨大挑战。此外，由于肿瘤的低免疫原性和免疫逃逸特性，免疫疗法在实体肿瘤的治疗中所取得的临床效果仍然有限。全文旨在对靶向BCSC免疫治疗的最新进展和存在问题进行总结与展望，从而为临床和科研工作带来更多新的思路。 |
| 英文摘要: |
| Abstract： Breast cancer is a highly aggressive malignant tumor. In recent years， the number of breast cancer cases in China has been increasing， and its high recurrence rate poses a serious threat to the survival of breast cancer patients. Tumor stem cells play an important role in the tumorigenesis of breast cancer and can be a key target for breast cancer treatment， therefore immunotherapy targeting breast cancer stem cells(BCSC) holds great promise. The immunotherapy targeting BCSC includes DC vaccines， CAR-T cells， immune checkpoint inhibitors， lysing viruses and monoclonal antibodies. However， the design of effective BCSC-targeting therapy faces challenges due to the lack of markers specific to BCSC； and the clinical effectiveness of immunotherapy for solid tumors remains limited due to the low immunogenicity and immune escape properties of tumors. In this review， we summarize the recent progress and related issues in targeted breast cancer stem cell immunotherapy， to provide reference for clinical application and further studies. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |